Mrs Angela Grech
Rheolwr Treial
- GrechA2@caerdydd.ac.uk
- Neuadd Meirionnydd, Ystafell 6ed Llawr, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS
Cyhoeddiad
2019
- Milne, P. et al. 2019. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances 3(20), pp. 3052-3061. (10.1182/bloodadvances.2019000197)
2016
- Ivey, A. et al. 2016. Assessment of minimal residual disease in standard-risk AML. New England Journal of Medicine 374(5), pp. 422-433. (10.1056/NEJMoa1507471)
2015
- Burnett, A. K. et al. 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncology 16(13), pp. 1295-1305. (10.1016/S1470-2045(15)00193-X)
- Khan, N. et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)
Erthyglau
- Milne, P. et al. 2019. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances 3(20), pp. 3052-3061. (10.1182/bloodadvances.2019000197)
- Ivey, A. et al. 2016. Assessment of minimal residual disease in standard-risk AML. New England Journal of Medicine 374(5), pp. 422-433. (10.1056/NEJMoa1507471)
- Burnett, A. K. et al. 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncology 16(13), pp. 1295-1305. (10.1016/S1470-2045(15)00193-X)
- Khan, N. et al. 2015. An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38 lowblasts. British Journal of Haematology 170(1), pp. 80-84. (10.1111/bjh.13398)